Hildegund C.J. Ertl

1. He, Z., Wlazlo, A.P., Kowalczyk, D., Cheng, J., Xiang, Z.Q., Giles-Davis, W. and Ertl, H.C.J. 2000. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology, 270: 146-161.
   
2. Oyaski, M. and Ertl, H.C.J. 2000. DNA Vaccines. Science & Medicine. 7: 30-43.
   
3. Otvos, L. Jr., Pease, A.M., Bokonyi, K., Giles-Davis, W., Rogers, M.E., Hintz, P.A., Hoffmann, R. and Ertl, H.C.J. 2000. In situ identification of T helper cell hybridoma with a cellulose-bound peptide antigen. J. Immuno. Meth. 233: 95-105.
   
4. Fields, P.A., Kowalczyk, D.W., Arruda, V.R., McCleland, M.L., Armstrong, E., Hagstrom, J.N., Pasi, K.J., Ertl, H.C.J., Herzog, R.W., High, K.A. 2000. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1: 225-35.
   
5. Tims, T. Briggs, D. J., Davis, R., Moore, S.M., Xiang, Z.Q. Ertl, H.C.J., Fu, Z.F. 2000. Dogs vaccinated with recombinant adenovirus glycoprotein develop high titers of neutralizing antibodies. Vaccine. 18: 2804-7.
   
6. Kowalczyk, D., Wlazlo, A.P., Giles-Davis, W., Ertl, H.C.J. 2000. Staining of antigen activated lymphocytes (SAAL): A highly specific method for amplification of tumor-specific CD8+ T cells. J. Immunol. Meth. 241: 131-139.
   
7. Otvos, Jr., L., Bokonyi, K., Varga, I., Otvos, B.I., Hoffmann, R., Ertl, H.C.J., Wade, J.D., McManus, A.M., Craik, D.J., Bulet, P. 2000. Insect peptides with improved protease-resistance protect mice against bacterial infection. Protein Science. 9: 742 – 749.
   
8. Wlazlo, A.P. Giles-Davis, W., Clements, A., Strubble, G., Marmorstein, R. and Ertl, H.C.J. 2001. Generation and characterization of monoclonal antibodies against the E6 and E7 oncoproteins of HPV-16. Hybridoma, 20: 257- 263.
   
9. Kowalczyk, D., Wlazlo, A.P., Shane, S., Ertl, H.C.J. 2001.Vaccine regimen for prevention of sexually transmitted human papillomavirus type 16. Vaccine 19: 3583-3590.
   
10. Reyes-Sandoval, A. and Ertl, H.C.J. 2001. DNA Vaccines. Curr. Mol. Med. 1: 217-243.
    
11. Wlazlo, A.P. and Ertl, H.C.J. 2001. DNA Tumor Vaccines. AITE 49:1-11.
    
12. Kowalczyk, D., Wlazlo, A., Blaszczyk-Thurin, M., Xiang, Z.Q., Giles-Davis, W., Ertl, H.C.J. 2001. A method that allows easy characterization of tumor-infiltrating lymphocytes. J. Immuno. Meth. 253: 163-175.
    
13. Farina, S.F., Gao, G., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., Marsh, J., Ertl, H.C.J., Wilson, J.M. 2001. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75: 11603-13.
    
14. Xiang, Z.Q., Gao, G., Reyes-Sandoval, A., Cohen, C.J., Li, Y., Bergelson, J.M., Wilson, J.M.,Ertl, H.C.J. 2002. Novel, adenoviral vaccine carrier based on the chimpanzee serotype 68 for induction of antibodies to a transgene product. J. Virol. 76: 2667-2675.
    
15. Blaszczyk-Thurin, M., O, I., Ertl, H.C.J. 2002. An experimental vaccine expressing wild-type p53 for prevention of cancer. Scand. J. Immunol. 56: 361-375.
    
16. Cohen, C.J., Xiang, Z.Q., Gao, G.P., Ertl, H.C.J., Wilson, J.M., and Bergelson, J.M. 2002. Chimpanzee adenovirus 68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J. Gen. Virol. 83: 151-155.
    
17. Kammer, A.R. and Ertl, H.C.J. 2002. Rabies Vaccines: From the Past to the 21st Century. Hybridoma and Hybridomics 21: 123-127.
    
18. Lees, C.Y., Briggs, D.J., Wu, X., Davis, R.D., Moore, S.M., Gordon, C., Xiang, Z., Ertl, H.C., Tang, de C.C., Fu, Z.F. 2002. Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. Vet. Microbiol. 85: 295-303.
    
19. O, I., Ku, G., Ertl, H.C.J. and Blaszczyk-Thurin, M. 2002. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res. 22: 613-621.
    
20. Cudic, M., Ertl, H.C.J., Otvos. L. 2002. Synthesis, conformation and T helper cell stimulation of an o-linked glycopeptide epitope containing extended carbohydrate side-chains. Bioorg. Med. Chem. 10: 3859 – 3870.
    
21. Ertl, H.C.J. 2002. Viral Immunology. In Fundamental Immunology, W.E. Paul, ed. Lippincott, Williams and Wilkins, Philadelphia, PA.
    
22. Vinner, L., Wee, E.G.T., Patel, S., Corbet, S., Gao, G.P., Therrien, D., Nielsen, C., Wilson, J.M., Ertl, H.C., Hanke, T., Fomsgaard, A. 2002. Immunogenicity in Mamu-A01 Rhesus Macques of a CR5-Tropic HIV-1 envelop from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus-5 boost. Statens Serum Institut web communiqué.
    
23. Deng, H., Kowalczyk, D.W., O, I., Blaszczyk-Thurin, M., Xiang, Z.Q., Giles-Davis, W., and Ertl, H.C.J. 2002. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line. Cell. Immunol. 215: 20-31.
    
24. Pinto AR, Ertl HC. 2002. Genetically modified adenoviruses as recombinant vaccines. Curr. Top. Virol. 2:69-84.
    
25. Ertl, H.C.J. 2003. Cytokines and immunomodulatory ligands as genetic adjuvants. DNA Vaccines, Ertl, H.C.J., ed. Landes Biosciece, Houston, TX & Kluwer Academic, Plenum Publishers, New York, NY.
    
26. DNA Vaccines. 2003. Ertl, H.C.J., ed. Landes Biosciece, Houston, TX & Kluwer Academic, Plenum Publishers, New York, NY.
    
27. Jackson, A.C., Mary J. Warrell, M.J., Rupprecht, C.E., C. J. Ertl, H.C., Dietzschold, B., O’Reilly, M., Leach, R.P., Fu, Z.F., Wunner, W.H., Bleck, T.P., and Wilde, H. 2003. Management of rabies in humans. Clin. Infect. Dis. 36: 60-63.
    
28. Fitzgerald, J., Gao, G.P., Reyes-Sandoval, A., Pavlakis, G.N., Xiang, Z.Q., Wlazlo, A.P., Giles-Davis, W., Wilson, J., and Ertl, H.C.J. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170: 1416-1422.
    
29. Xiang, Z.Q., Gao, G.P., Li, Y., Wilson, J.M., Ertl, H.C. 2003. T Helper cell-independent antibody responses to the transgene product of the E1-deleted adenoviral vaccine require NK1.1 T cells. Virology 305: 397-405.
    
30. Vinner, L., Wee, EG, Patel, S., Corbet, S., Gao, GP, Nielsen, C., Wilson, J.M., Ertl, H.C.J., Hanke, T., Fomsgaard, A. 2003. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J. Gen. Virol., 84: 203-213.
    
31. Ertl, H.C.J. 2003. Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. Curr. Opin. Mol. Ther. 4:601-605.
    
32. Ertl, H.C.J. 2003. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opinion on Biol. Ther. 3: 639-644.
    
33. Pinto, A.R., Reyes-Sandoval, A., Ertl, H.C.J. 2003. Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell. Immunol. 224: 106-113.
    
34. Kowalczyk, D.K., Wlazlo, A.P., Giles-Davis, W., Kammer, A.R., Mukhopadhyay, S., and Ertl, HC.J. 2003. Vaccine-induced CD8+ T cells eliminate tumors by two staged attack. Cancer Gene Ther. 10: 870 –878.
    
35. Xiang, Z.Q., Gao, G.P., Reyes-Sandoval, A., Li, Y., Wilson, J.M., Ertl, H.C. 2003. Oral vaccination with adenoviral vectors is not impaired by pre-existing immunity to the vaccine carrier. J. Virol. 77:10780-9.
    
36. Pinto, A.R., Fitzgerald, J.C., Gao, G.P., Wilson, J.M., and Ertl, H.C.J. 2004. Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. Vaccine. 22: 697-703.
    
37. Pinto, A.R., Fitzgerald, J.C., Giles-Davis, W., Gao, G.P., Wilson, J.M., and Ertl, H.C.J. 2003. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171: 6774-6779.
    
38. Xiang, Z.Q. Li, Y., Gao, G.P., Wilson, J.M. and Ertl, H.C.J. 2003. Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice J. Immunol, 171: 4287 – 4293.
    
39. Reyes-Sandoval, A. Ertl, H.C.J. 2004. CpG-methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses Mol. Ther. 9: 249-261.
    
40. Lasaro, M.O., Ertl, H.C. 2004. Human papillomavirus-associated cervical cancer: Prophyllactic and therapeutic vaccines. Gene Ther Mol Biol. 8: 291-306.
    
41. Reyes-Sandoval, A. Fitzgerald, J.C., Grant, R., Roy, S. Xiang, Z.Q. Li, Y., Gao, G.P., Wilson, J.M., and Ertl, H.C.J. 2004. Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J.Virol. 78: 7392-7399.
    
42. Wlazlo, A.P., Deng, H., Giles-Davis, W., Ertl, H.C.J. 2004. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins Cancer Gene Ther. 11: 457-464.
    
43. Vanniasinkam,, T., Ertl, H.C.J. 2004. Rabies Vaccines: The Third Generation. Drug Design and Discovery. 1:289-292.
    
44. Tatsis, N., Ertl, H.C.J. 2004. Adenoviruses as vaccine vectors. Mol Ther. 10: 616-629.
    
45. Vanniasinkam, T., Ertl, H.C. 2005. Adenoviral gene delivery for HIV-1 vaccination Curr Gene Ther. 5:203-12.
    
46. Ertl, H.C. 2005. Immunological insights from genetic vaccines. Virus Res. 111:89-92.
    
47. Manno, C.S., Pierce, G.F., Glader, B., Arruda, V.R., Ragni, M., Rasko, J., Ozelo, M., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Nakai, H., Chew, A., Leonard, D.G.B., Wright, J.F., Sommer, J., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Couto, L., Ertl, H.C., High, K.A., Kay, M.A. AAV -mediated, liver-directed gene transfer for severe hemophilia B: successful transduction and limitations imposed by the host immune response. Nat Med, e-pub February 12, 2006.
    
48. Ertl, H.C. 2005. Challenges of immune responses in gene replacement therapy. IDrug. 8:736-738.
    
49. Tatsis, N., Tesema, L., Robinson, E., Giles-Davis, W., McCoy, K., Gao, G.P., Wilson, J.M., Ertl, H.C. 2006. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Therapy, 13: 421-429.
    
50. Vanniasinkam, T., Reddy, S. T., Ertl, H.C. 2005. DNA immunization using a non-viral promoter. Virology. 344:412-420.
    
51. Hensley, S.E., Giles-Davis, W., McCoy, K.C., Weninger, W., Ertl, H.C. 2005. Dendritic Cell Maturation, but Not CD8 T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors. J. Immunol., 175: 6032-6041.
    
52. Lasaro, M.O., Diniz, M.O., Reyes-Sandoval, A., Ertl, H.C., Ferreira, L.C. 2005. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes Infect. Epub. Oct. 4.
    
53. D. Briggs, Dr H. Bourhy, S. Cleaveland, F. Cliquet, , H. Ertl, A. Fayaz, A. Fooks, T. Hemachudha, R. L. Ichhpujani, W. R. Kaboyo, H. Koprowski, S. N. Madhusudana, T. Müller, L. Nel, B. Quiambao, C. E. Rupprecht, N. Salahuddin, M. K. Sudarshan, N. Tordo, A. I. Wandeler, H. Wilde. 2005. WHO Expert Consultation on Rabies. WHO Technical Report Series 931
    
54. Sabatino, D.E., Mingozzi, F., Hui, D.J., Chen, H., Colosi, P., Ertl, H.C., High, K.A. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Molecular Therapy. 12:1023-1033.
    
55. Zhou, D., Ertl, H.C. 2005. Therapeutic potential of adenovirus as vaccine vector. Exp Opin Biol Ther. 6:63-72.
    
56. Zhou, D., Li, Y., Xiang, Z.Q., Ertl, H.C. 2006. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Submitted, Mol Ther.